Détails du produit
Synonyms
GM-CSF, CSF2, MGC131935
Source
Mouse GM-CSF Protein, Tag Free (GMF-M5211) is expressed from human 293 cells (HEK293). It contains AA Ala 18 - Lys 141 (Accession # P01587).
Predicted N-terminus: Ala 18
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 14.1 kDa. The protein migrates as 17-23 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Sterility
Negative
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Mouse GM-CSF Protein, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA

Immobilized Mouse GM-CSF Protein, Tag Free (Cat. No. GMF-M5211) at 5 μg/mL (100 μL/well) can bind Mouse GM-CSF R alpha Protein, His Tag (Cat. No. GMA-M52H3) with a linear range of 0.01-0.156 μg/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Macrophage colony stimulating factor 2
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
9 Détails
- Étape de développement la plus élevée:
NDA/BLA



















